Compare prices and buy BPC-157 + TB-500 + KPV Blend from 3 research peptide vendors - also called suppliers or sources. Updated daily.
A research blend of BPC-157, TB-500 and KPV. BPC-157 is a synthetic fragment of a protein isolated from human gastric juice, TB-500 is sold as either full-length thymosin beta-4 or its short actin-binding fragment depending on the vendor, and KPV is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. The three act through unrelated mechanisms studied in cell and animal models, and no published study has tested the combination. None of the three is FDA-approved.
For research purposes only. Not medical advice.
The BPC-157, TB-500 and KPV blend combines three research peptides in one product: BPC-157, TB-500 and KPV. As a mixture it has no CAS number of its own, so a certificate of analysis should report each component separately.
It sits in the middle of a blend family. It is Wolverine with KPV added, KLOW without the copper peptide GHK-Cu, and BPC-157 + KPV with TB-500 added. As of October 2026, PeptideScouter indexes it in two formats, a vial and a spray.
BPC-157 is a synthetic 15-residue fragment of a protein isolated from human gastric juice, and its proposed mechanisms, among them nitric oxide signaling and VEGFR2 upregulation, come from cell-culture and rodent injury studies. Thymosin beta-4 is a 43-residue protein that binds monomeric G-actin and so regulates cytoskeletal assembly, and in laboratory models it promotes cell migration and angiogenesis. Its seven-residue fragment carries the actin-binding motif. KPV, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone, lacks the sequence its parent uses to bind melanocortin receptors, and cell and rodent work describes it entering cells through the PepT1 transporter and suppressing NF-kB signaling.
The three share no sequence, no origin and no mechanism, so selling them together is a market convention rather than a pharmacological one. Each component's page carries its evidence and its limits.
A PubMed search on October 21, 2026 for BPC-157 under its common names together with KPV, Lys-Pro-Val or alpha-MSH and with TB-500 or thymosin beta-4 returned one article, a 2026 review of the FDA compounding advisory committee's peptide recommendations. A Europe PMC search the same day, which also reaches full text, returned that review and a second 2026 review of therapeutic peptides. Neither is a study of the three together. ClinicalTrials.gov listed no study with KPV as an intervention that day, so no registered trial combines it with the other two.
A title naming "TB-500" does not say whether the product holds full-length TB-500 Thymosin Beta-4 or the seven-residue TB-500 Frag 17-23, which PeptideScouter indexes as separate rows. The Wolverine page covers that ambiguity in full. On October 21, 2026, the product page of a spray listing for this blend gave its TB-500 component the molecular formula of the full 43-residue chain and listed no CAS number for it. The certificate of analysis is the check.
PeptideScouter records a blend's size as the vial's total peptide content, so the vial's per-milligram figure is spread across three peptides. It compares only to a mass-weighted average of the three component prices, the arithmetic the KLOW page sets out, and which TB-500 the vial holds moves that benchmark. The spray is indexed but carries no per-milligram figure, because the site computes one only for vials whose contents are stated in milligrams.
None of the three is an FDA-approved drug. BPC-157, KPV and the seven-residue TB-500 fragment have moved through FDA's compounding review in step: all three were placed in Category 2, left it in the same 2026 announcement and went before the Pharmacy Compounding Advisory Committee in July 2026. Their pages carry the dates, the votes and FDA's reviews. Full-length thymosin beta-4 was not the substance at any of those steps, so the arc splits on which TB-500 the vial holds.
The blend itself was never reviewed, because nominations are made per substance. Committee votes are advisory, and the list changes only through notice-and-comment rulemaking. Our writeup of the July 2026 vote covers all seven substances heard that week.
No title recorded here says whether each peptide is the free base or the acetate, the two forms FDA's July 2026 agenda named for each of the three. The certificate of analysis is the check for salt form as well as for TB-500.
Three research peptides in one product: BPC-157, a synthetic 15-amino-acid fragment of a protein isolated from human gastric juice, TB-500, sold as either full-length thymosin beta-4 or its seven-residue actin-binding fragment, and KPV, the tripeptide Lys-Pro-Val from the C-terminus of alpha-melanocyte-stimulating hormone. The blend has no CAS number of its own because it is a mixture, so a certificate of analysis should report each component separately.
The product titles PeptideScouter has recorded for this blend do not say. The name TB-500 is used for two different molecules: full-length thymosin beta-4, a 43-amino-acid protein with CAS 77591-33-4, and an N-acetylated seven-residue fragment of it covering residues 17 to 23, CAS 885340-08-9. The CAS number or molecular formula on the certificate of analysis is the only reliable check. The answer also decides which FDA review applies, because the substance the FDA's advisory committee considered under the TB-500 name in July 2026 was the fragment.
PeptideScouter computes a price per milligram only for vials whose contents are stated in milligrams. A spray is a different format, so its listing is indexed but left out of every per-milligram median and comparison on the site. The vial version does carry a per-milligram figure, but it is spread across three peptides, so it compares only to a mass-weighted average of the three component prices, not to a single-peptide vial.
No study of the three together turned up. A PubMed search on October 21, 2026 for BPC-157 together with KPV and with TB-500 or thymosin beta-4 returned a single review article, a Europe PMC search the same day added one more review, and ClinicalTrials.gov listed no study with KPV as an intervention. Each peptide has its own preclinical literature, and the combination is a market convention rather than a pharmacological one.
No. Nominations to the Section 503A bulk drug substances list are made per substance, and no combination product was on the agenda of the Pharmacy Compounding Advisory Committee's July 23-24, 2026 meeting. BPC-157, KPV and the seven-residue TB-500 fragment were each heard separately there, and the committee voted to recommend adding each. Full-length thymosin beta-4 was not on the agenda. Those votes are advisory, and the FDA changes the list only through notice-and-comment rulemaking.
BPC-157 + TB-500 + KPV Blend is sold by 3 research peptide vendors indexed on PeptideScouter, with 3 tracked listings compared per vendor in the table above. Pricing is normalized and refreshed daily.
2 of the 3 indexed vendors currently have BPC-157 + TB-500 + KPV Blend in stock. The comparison table marks out-of-stock listings, and stock state is refreshed daily.
ION Peptide currently lists BPC-157 + TB-500 + KPV Blend at $3.97/mg, the lowest listed price across 3 tracked research peptide vendors. With current vendor discount codes applied, the lowest effective price is $3.37/mg.
Discount codes are issued per vendor rather than per peptide, so any code applies across that vendor's whole catalog. All 3 vendors listing BPC-157 + TB-500 + KPV Blend publish a PeptideScouter code, worth 10% to 15% off. Applied, the lowest effective price falls from $3.83/mg listed to $3.37/mg at ION Peptide. Each vendor's code is shown beside its price in the table above.
BPC-157 + TB-500 + KPV Blend ranges from $3.83/mg to $3.97/mg across 3 listings from 3 research peptide vendors, normalized to USD per milligram and refreshed daily.
3 research peptide vendors currently list BPC-157 + TB-500 + KPV Blend on PeptideScouter, with 2 in stock right now. We track 3 listings across size and kit variants.
